Structures by: Zerzouf A.
Total: 18
Ethyl 3-methyl-1-oxo-4<i>H</i>-1,4-benzothiazine-2-carboxylate monohydrate
C12H13NO3S,H2O
IUCrData (2018) 3, 6 x180887
a=8.8340(3)Å b=18.6849(6)Å c=7.6927(3)Å
α=90° β=91.4780(10)° γ=90°
1-(1,3-Benzothiazol-2-yl)propan-2-ol
C10H11NOS
Acta Crystallographica Section E (2005) 61, 9 o3027-o3029
a=15.7702(11)Å b=7.8856(4)Å c=15.8703(11)Å
α=90° β=101.135(5)° γ=90°
C18H17NO4S
C18H17NO4S
Acta Crystallographica Section E (2001) 57, 4 o362-o363
a=13.6308(8)Å b=15.1336(9)Å c=16.1540(10)Å
α=90.000(4)° β=151.086(3)° γ=90.000(10)°
Methyl 2-oxo-2,3-dihydro-1,3-benzothiazole-3-acetate
C10H9NO3S
Acta Crystallographica Section E (2005) 61, 11 o3872-o3873
a=4.7858(3)Å b=12.4010(7)Å c=17.5319(10)Å
α=90° β=95.679(5)° γ=90°
Methyl (2-benzylidene-3-oxo-1,4-benzothiazin-4-yl)acetate
C18H15NO3S
Acta Crystallographica Section E (2001) 57, 6 o498-o499
a=19.0388(6)Å b=9.6511(3)Å c=20.9817(6)Å
α=90.0° β=155.4920(10)° γ=90.0°
Ethyl 3-methyl-1-oxo-4H-1,4-benzothiazine-2-carboxylate
C12H13NO3S
Acta Crystallographica Section E (2005) 61, 8 o2716-o2717
a=12.9935(13)Å b=33.042(4)Å c=11.1555(13)Å
α=90° β=90° γ=90°
4-[(3-Hydroxy-5-phenyl-1H-pyrazol-4-yl)methyl]-5-phenyl-1H-pyrazol-3(2H)-one
C19H16N4O2
Acta Crystallographica Section E (2007) 63, 5 o2554-o2556
a=9.2908(10)Å b=16.4731(15)Å c=11.0153(13)Å
α=90.00° β=106.903(8)° γ=90.00°
1-(1-Nonyl-2-oxoindolin-3-ylidene)thiosemicarbazide
C18H26N4OS
Acta Crystallographica Section E (2010) 66, 6 o1332
a=11.5343(2)Å b=10.5921(2)Å c=15.6262(3)Å
α=90.00° β=95.9220(10)° γ=90.00°
1-(1-Decyl-2-oxoindolin-3-ylidene)thiosemicarbazide
C19H28N4OS
Acta Crystallographica Section E (2010) 66, 6 o1333
a=11.8856(2)Å b=11.0055(2)Å c=15.1638(3)Å
α=90.00° β=99.4680(10)° γ=90.00°
(<i>E</i>)-4-(2,3-Dihydro-1,3-benzothiazol-2-ylidene)-3-methyl-1-phenyl- 1<i>H</i>-pyrazol-5(4<i>H</i>)-one
C17H13N3OS
Acta Crystallographica Section E (2010) 66, 5 o1096
a=27.0144(8)Å b=7.4021(2)Å c=14.0523(4)Å
α=90.00° β=97.4660(10)° γ=90.00°
3-(Benzothiazol-2-yl)-3-(prop-2-ynyl)hex-5-yn-2-one
C16H13NOS
Acta Crystallographica Section E (2010) 66, 4 o857
a=7.79130(10)Å b=30.2051(6)Å c=12.4437(2)Å
α=90.00° β=106.1610(10)° γ=90.00°
4-(1,3-Benzothiazol-2-yl)-5-methyl-2-phenyl-1-propynyl- 1<i>H</i>-pyrazol-3(2<i>H</i>)-one
C20H15N3OS
Acta Crystallographica Section E (2010) 66, 11 o2843
a=4.82210(10)Å b=9.3698(2)Å c=37.6990(9)Å
α=90.00° β=90.00° γ=90.00°
1-Allyl-4-(1,3-benzothiazol-2-yl)-5-methyl-2-phenyl- 1<i>H</i>-pyrazol-3(2<i>H</i>)-one
C20H17N3OS
Acta Crystallographica Section E (2010) 66, 11 o2842
a=17.8734(5)Å b=10.4297(2)Å c=18.9578(4)Å
α=90.00° β=90.00° γ=90.00°
4-(Prop-2-ynyl)-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C11H9NOS
Acta Crystallographica Section E (2014) 70, 6 o641
a=9.005(2)Å b=10.889(3)Å c=10.341(3)Å
α=90.00° β=104.565(7)° γ=90.00°
Ethyl 2-{5-[(3-oxo-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-4-yl)methyl]-1<i>H</i>-1,2,3-triazol-1-yl}acetate
C15H16N4O3S
Acta Crystallographica Section E (2014) 70, 2 o116
a=5.6414(2)Å b=11.1604(4)Å c=13.3724(5)Å
α=73.823(2)° β=87.226(2)° γ=88.566(2)°
4-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C18H16N4OS
Acta Crystallographica Section E (2014) 70, 2 o160-o161
a=13.283(2)Å b=5.3661(10)Å c=23.281(4)Å
α=90.00° β=96.633(10)° γ=90.00°
4-(1,3-Benzothiazol-2-yl)-1,5-dimethyl-2-phenyl-1<i>H</i>-pyrazol- 3(2<i>H</i>)-one
C18H15N3OS
Acta Crystallographica Section E (2011) 67, 10 o2700
a=8.7428(2)Å b=25.7551(5)Å c=6.96600(10)Å
α=90.00° β=97.4600(10)° γ=90.00°
(2<i>Z</i>)-2-Benzylidene-4-(prop-2-yn-1-yl)-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C18H13NOS
Acta Crystallographica Section E (2014) 70, 5 o614
a=9.0254(13)Å b=7.7388(12)Å c=42.488(7)Å
α=90.00° β=90.00° γ=90.00°